885277-01-0

Basic information

• Product Name: 2-CHLORO-4-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE
• Synonyms: 2-CHLORO-4-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE;Pyridine, 2-chloro-4-(2,2,2-trifluoroethoxy)-
• CAS NO: 885277-01-0
• Molecular Formula: C7H5ClF3NO
• Molecular Weight: 211.57
• Mol File: 885277-01-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 213.6±40.0 °C(Predicted)
• Appearance: /
• Density: 1.396±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.40±0.10(Predicted)
• CAS DataBase Reference: 2-CHLORO-4-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-4-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE(885277-01-0)
• EPA Substance Registry System: 2-CHLORO-4-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE(885277-01-0)

Safety Data

• Hazardous Substances Data: 885277-01-0(Hazardous Substances Data)

Usage

General Description

2-CHLORO-4-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE is a chemical compound with the molecular formula C7H4ClF3NO. It is a clear, colorless liquid that is primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 2-CHLORO-4-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE is also used in the production of herbicides, pesticides, and insecticides. It is classified as a chloropyridine, which is a type of organic compound containing a pyridine ring with a chlorine atom attached to it. 2-CHLORO-4-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDINE is considered to be a hazardous substance and should be handled with caution due to its potential for causing skin and eye irritation.

Upstream product

• 34941-91-8 2-chloro-4-fluoropyridine 
• 75-89-8 2,2,2-trifluoroethanol 
• 23056-36-2 2-chloro-4-nitropyridine 

Relevant articles and documents

Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties

Inhibition of glutaminase-1 (GLS-1) hampers the proliferation of tumor cells reliant on glutamine. Known glutaminase inhibitors have potential limitations, and in vivo exposures are potentially limited due to poor physicochemical properties. We initiated a GLS-1 inhibitor discovery program focused on optimizing physicochemical and pharmacokinetic properties, and have developed a new selective inhibitor, compound 27 (IPN60090), which is currently in phase 1 clinical trials. Compound 27 attains high oral exposures in preclinical species, with strong in vivo target engagement, and should robustly inhibit glutaminase in humans.